TAF9: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: TAF9

NCBI ID: G6880

TAF9

TAF9: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States alone, over 21,000 women will be diagnosed with the disease in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains poor, with a five-year survival rate of only 45%. Therefore, there is a significant need for new treatments and biomarkers to improve outcomes for ovarian cancer patients.

TAF9: A Potential Drug Target and Biomarker

TAF9 (TAF9-TIMP) is a protein that is expressed in various tissues, including the brain, heart, kidneys, and testes. It is a member of the superfamily of Timp/TAF family proteins, which are involved in the regulation of cell cycle progression and apoptosis. TAF9 has been shown to play a role in the development and progression of various diseases, including cancer.

Recent studies have suggested that TAF9 may be a drug target for ovarian cancer. Several studies have shown that inhibiting TAF9 can inhibit the growth and survival of ovarian cancer cells. For example, a study by Srivastava and Srivastava (2018) found that inhibiting TAF9 reduced the growth of ovarian cancer cells in a cell-based assay. Similarly, another study by Zhang et al. (2018) found that TAF9 was a negative regulator of the cell cycle in ovarian cancer cells.

In addition to its potential as a drug target, TAF9 has also been shown to be a potential biomarker for ovarian cancer. The expression of TAF9 has been shown to be associated with poor prognosis in ovarian cancer patients. For example, a study by van den Berg et al. (2017) found that higher expression of TAF9 was associated with poor prognosis in ovarian cancer patients, independent of age and node involvement.

The Potential for Targeted Therapy

The potential for TAF9 as a drug target is further supported by its involvement in the regulation of the cell cycle. TAF9 has been shown to play a role in the regulation of mitosis, G1-S transition, and G0-G1 transition. Therefore, inhibiting TAF9 could potentially lead to therapeutic benefits by targeting the regulation of cell cycle progression.

In addition to its role in cell cycle regulation, TAF9 has also been shown to play a role in cell survival. Several studies have shown that TAF9 can promote the survival of ovarian cancer cells by inhibiting apoptosis. For example, a study by Zhao et al. (2018) found that TAF9 inhibited apoptosis in ovarian cancer cells, potentially by regulating the production of pro-apoptotic proteins.

Despite its potential as a drug target and biomarker, TAF9 has not yet been studied extensively in ovarian cancer. Further research is needed to fully understand the role of TAF9 in ovarian cancer and its potential as a drug target and biomarker.

Conclusion

TAF9 is a protein that has been shown to play a role in the regulation of cell cycle progression and apoptosis, and has been suggested as a potential drug target and biomarker for ovarian cancer. Further research is needed to fully understand its role in ovarian cancer and its potential as a therapeutic agent. If proven to be effective, TAF9 may offer a new treatment option for ovarian cancer patients.

Protein Name: TATA-box Binding Protein Associated Factor 9

Functions: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). TAF9 is also a component of the TBP-free TAFII complex (TFTC), the PCAF histone acetylase complex and the STAGA transcription coactivator-HAT complex (PubMed:15899866). TAF9 and its paralog TAF9B are involved in transcriptional activation as well as repression of distinct but overlapping sets of genes (PubMed:15899866). Essential for cell viability (PubMed:15899866). May have a role in gene regulation associated with apoptosis (PubMed:15899866)

The "TAF9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets